The following announcement is shared with you on behalf of the Medical Radiation Safety Committee (MRSC) and Radioactive Drug Research Committee (RDRC):
As mentioned during the launch of the New SafetyNet system for the MRSC/RDRC, effective January 2, 2019, all approved MRSC/RDRC submissions, including those migrated into the new system, will be subject to continuing review (CR). CR email notifications with instructions will be sent 60 days prior to expiration. CR will be required for MRSC studies every three years and every quarter for RDRC protocols. If your study has ended, please close it in SafetyNet at your earliest convenience.
For more information about MRSC/RDRC review and requirements, visit the MRSC web page.
Please contact the RSC administrative team at RSC@research.ucla.edu or (310) 206-5601 for more information.